|
1
|
Read WL, Page NC, Tierney RM, Piccirillo
JF and Govindan R: The epidemiology of bronchioloalveolar carcinoma
over the past two decades: Analysis of the SEER database. Lung
Cancer. 45:137–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koma Y, Nakashima N, Koyama M, Goto K,
Yokota N, Kimura K, Matsumoto Y, Yoshida C, Matsuoka H, Masuya D,
et al: Two cases of recurrent invasive mucinous adenocarcinoma of
the lung showing marked responses to platinum-based
chemotherapyregimens with pemetrexed and bevacizumab. Gan To Kagaku
Ryoho. 40:1525–1528. 2013.(In Japanese). PubMed/NCBI
|
|
3
|
Yamakawa H, Takayanagi N, Ishiguro T,
Kagiyama N, Shimizu Y and Sugita Y: A favorable response to
cisplatin, pemetrexed and bevacizumab in two cases of invasive
mucinous adenocarcinoma formerly known as pneumonic-type mucinous
bronchioloalveolar carcinoma. Intern Med. 52:2781–2784. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G,
Garg K, et al: International Association for the Study of Lung
Cancer/American Thoracic Society/European Respiratory Society:
International multidisciplinary classification of lung
adenocarcinoma: Executive summary. Proc Am Thorac Soc. 8:381–385.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masuzawa K, Minematsu N, Sasaki M, Ohsawa
K, Yamamoto T, Iwamaru A, Ogata K, Betsuyaku T and Murakami M:
Invasive mucinous adenocarcinoma of the lung presenting as a large,
thin-walled cyst: A case report and literature review. Mol Clin
Oncol. 6:433–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Levy BP, Drilon A, Makarian I, Patel AA
and Grossbard ML: Systemic approaches for multifocal
bronchioloalveolar carcinoma: Is there an appropriate target?
Oncology (Williston Park). 24(888–898): 9002010.PubMed/NCBI
|
|
7
|
Whitson BA, Groth SS, Andrade RS, Mitiek
MO, Maddaus MA and D'Cunha J: Invasive adenocarcinoma with
bronchoalveolar features: A population-based evaluation of the
extent of resection in bronchoalveolar cell carcinoma. J Thorac
Cardiovasc Surg. 143(591–600): e12012.PubMed/NCBI
|
|
8
|
Miller VA, Hirsch FR and Johnson DH:
Systemic therapy of advanced bronchioloaIveolar cell carcinoma:
Challenges and opportunities. J Clin Oncol. 23:3288–3293. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kris MG, Giaccone G, Davies A, Fukuoka M,
Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Van
Meerbeeck JP and West H: Systemic therapy of bronchioloalveolar
carcinoma: Results of the first IASLC/ASCO consensus conference on
bronchioloalveolar carcinoma. J Thorac Oncol. 1 9 Suppl:S32–S36.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scagliotti GV, Smit E, Bosquee L, O'Brien
M, Ardizzoni A, Zatloukai P, Eberhardt W, Smid-Geirnaerdt M, de
Bruin HG, Dussenne S, et al: A phase II study of paclitaxel in
advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung
Cancer. 50:91–96. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
West HL, Crowley JJ, Vance RB, Franklin
WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M,
Chansky K, et al: Advanced bronchioloalveolar carcinoma: A phase II
trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest
Oncology Group study. Ann Oncol. 16:1076–1080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dziadziuszko R, Siemiatkowska A, Limon J,
Rzyman W, Jassem J, Bunn PA Jr, Varella-Garcia M and Hirsch FR:
Unusual chemosensitivity of advanced bronchioalveolar carcinoma
after gefitinib response and progression: A case report. J Thorac
Oncol. 2:91–92. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dirican N, Baysak A, Cok G, Goksel T and
Aysan T: Clinical characteristics of patients with
bronchioloalveolar carcinoma: A retrospective study of 44 cases.
Asian Pac J Cancer Prev. 14:4365–4368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo J, Wang R, Han B, Zhang J, Zhao H,
Fang W, Luo Q, Yang J, Yang Y, Zhu L, et al: Analysis of the
clinicopathologic characteristics and prognostic of stage I
invasive mucinous adenocarcinoma. J Cancer Res Clin Oncol.
142:1837–1845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Joerger M, Omlin A, Cerny T and Früh M:
The role of pemetrexed in advanced non-small cell lung cancer:
Special focus on pharmacology and mechanism of action. Curr Drug
Targets. 11:37–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okuda C, Kim YH, Takeuchi K, Togashi Y,
Masago K, Sakamori Y, Mio T and Mishima M: Successful treatment
with pemetrexed in a patient with mucinous bronchioloalveolar
carcinoma: Long-term response duration with mild toxicity. J Thorac
Oncol. 6:641–642. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lau DH, Moon J, Davies AM, Sanborn RE,
Hirsch FR, Franklin WA, Ruzich JC, Redman MW and Gandara DR:
Southwestern oncology group phase II trial (S0526) of pemetrexed in
bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma.
Clin Lung Cancer. 14:351–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Manson GV and Ma PC: Response to
pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar
carcinoma insensitive to erlotinib. Clin Lung Cancer. 11:57–60.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duruisseaux M, Baudrin L, Quoix E, Wislez
M, Moro-Sibilot D, Coëtmeur D, Monnet I, Mourlanette P, Morère JF,
Soria JC, et al: Chemotherapy effectiveness after first-line
gefitinib treatment for advanced lepidic predominant adenocarcinoma
(formerly advanced bronchioloalveolar carcinoma): Exploratory
analysis of the IFCT-0401 trial. J Thorac Oncol. 7:1423–1431. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roviello G, Francini E, Perrella A, Laera
L, Mazzei MA, Guerrini S and Petrioli R: An exceptional overall
survival using bevacizumab beyond progression in a patient with
non-small cell lung cancer. Cancer Biol Ther. 16:1720–1725. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arjaans M, Schröder CP, Oosting SF, Dafni
U, Kleibeuker JE and de Vries EG: VEGF pathway targeting agents,
vessel normalization and tumor drug uptake: From bench to bedside.
Oncotarget. 7:21247–21258. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Adjei AA, Mandrekar SJ, Dy GK, Molina JR,
Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild
SE and Zinner RG: Phase II trial of pemetrexed plus bevacizumab for
second-line therapy of patients with advanced non-small cell lung
cancer: NCCTG and SWOG study N0426. J Clin Oncol. 28:614–619. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang GC, Yang TY, Wang NS, Huang CM and
Chiang CD: Successful treatment of multifocal bronchioloalveolar
cell carcinoma with ZD1839 (Iressa) in two patients. J Formos Med
Assoc. 102:407–411. 2003.PubMed/NCBI
|
|
24
|
Yano S, Kanematsu T, Miki T, Aono Y, Azuma
M, Yamamoto A, Uehara H and Sone S: A report of two
bronchioloalveolar carcinoma cases which were rapidly improved by
treatment with the epidermal growth factor receptor tyrosine kinase
inhibitor ZD1839 (‘Iressa’). Cancer Sci. 94:453–458. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bayle S, Descourt R, Gouva S, Daniel C and
Robinet G: Efficacy of gefitinib (Iressa) in the treatment of an
inoperable bronchioloalveolar cell carcinoma. Rev Mal Respir.
21:153–157. 2004.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kitazaki T, Fukuda M, Soda H and Kohno S:
Novel effects of gefitinib on mucin production in
bronchioloalveolar carcinoma; two case reports. Lung Cancer.
49:125–128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Milton DT, Kris MG, Gomez JE and Feinstein
MB: Prompt control of bronchorrhea in patients with
bronchioloalveolar caricinoma treated with gefitinib (Iressa).
Support Care Cancer. 13:70–72. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taja-Chayeb L, Candelaria M, Brom R,
Trejo-Becerril C, Meza F and Duenas-Gonzalez A: Response to
gefitinib in bronchioloalveolar carcinoma in the absence of EGFR
mutation. Lung Cancer. 50:259–263. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
West HL, Franklin WA, McCoy J, Gumerlock
PH, Vance R, Lau DH, Chansky K, Crowley JJ and Gandara DR:
Gefitinib therapy in advanced bronchioloalveolar carcinoma:
Southwest Oncology Group Study S0126. J Clin Oncol. 24:1807–1813.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kijima T, Suzuki M, Ueda K, Minami S,
Takeda Y, Goya S, Matsuoka H, Kumagai T, Yoshida M, Osaki T, et al:
Short-term gefitinib treatment brought about a long-term regression
of bronchioloalveolar carcinoma without EGFR gene alterations: A
case report. Oncol Res. 16:489–495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cadranel J, Quoix E, Baudrin L,
Mourlanette P, Moro-Sibilot D, Morere JF, Souquet PJ, Soria JC,
Morin F and Milleron B: IFCT-0401 Trial Group: IFCT-0401 trail: A
phase II study of gefitinib administered as first-line treatment in
advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
J Thorac Oncol. 4:1126–1135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Popat N, Raghavan N and Mclvor RA: Severe
bronchorrhea in a patient with bronchioloalveolar carcinoma. Chest.
141:513–514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miller VA, Riely GJ, Zakowski MF, Li AR,
Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, et
al: Molecular characteristics of bronchioloalveolar carcinoma and
adenocarcinoma, bronchioloalveolar carcinoma subtype, predict
response to erlotinib. J Clin Oncol. 26:1472–1478. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yuyama K, Matsushita H, Egawa K, Osawa T,
Tsubouchi Y, Takahashi T and Miura H: A case of bronchioloalveolar
carcinoma successfully treated with low-dose, alternate-day
administration of erlotinib. Gan To Kagaku Ryoho. 39:433–435.
2012.(In Japanese). PubMed/NCBI
|
|
35
|
Rubiales Sanz A, de la Cruz V, Berezo JÁ
and Torres MÁ: Erlotinib or gefitinib as first-choice therapy for
bronchorrhea in bronchioloalveolar carcinoma. J Pain Symptom
Manage. 47:e7–e9. 2014. View Article : Google Scholar
|
|
36
|
Garfield DH, Cadranel J and West HL:
Bronchioloalveolar carcinoma: The case for two diseases. Clin Lung
Cancer. 9:24–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cha YJ, Kim HR, Lee HJ, Cho BC and Shim
HS: Clinical course of stage IV invasive mucinous adenocarcinoma of
the lung. Lung Cancer. 102:82–88. 2016. View Article : Google Scholar : PubMed/NCBI
|
